HealthMore in Health→
Oral KRAS G12D Inhibitor GFH375 Tested in Phase 1 Solid Tumor Trial
Key Takeaways
- Nature Medicine published a phase 1 trial of GFH375 in previously treated advanced solid tumors with KRAS G12D mutations.
- GFH375 is described as an oral, dual on–off binding KRAS G12D inhibitor.
- The publication date is 15 September 2026, with DOI 10.1038/s41591-026-04559-4.
- Available metadata does not include efficacy, safety, dosing, or response-rate results.
DE
DT Editorial Team··via nature.com